There is a version of the life sciences CEO that the industry tends to celebrate: visionary, decisive, comfortable with risk.
Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan ...
Novartis investors are placing increased pressure on Novartis’ dealmaking strategy after facing setbacks to drugs acquired ...
The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human ...
Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following ...
An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...
The health care industry has invested heavily in point solutions ($100 billion). We have one tool for scheduling, another for ...
This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr ...
Our survey findings highlight the critical need for reforms to ensure that IBD patients can access the medications they need ...
Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 ...
Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...
GLP-1 medications might be most well-known as weight-loss options, but they were originally developed as a treatment for type 2 diabetes. For many patients, the drugs remain a highly effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results